Seeking Alpha

One possible partner for MannKind (MNKD +9% would be Pfizer (PFE -0.5%), according to a Motley...

One possible partner for MannKind (MNKD +9% would be Pfizer (PFE -0.5%), according to a Motley Fool article published over the weekend. Not only does MNKD desperately need a partner, but PFE is also in equal need of a new blockbuster drug. So, with MNKD's Afrezza near complete on its clinical trials, the synergies appear, on the surface at least, to be a natural fit.
From other sites
Comments (7)
  • taplinger
    , contributor
    Comments (270) | Send Message
    Wait a minute, what am I missing here? A drug firm with a successful trial doesn't need help except counting its money.
    27 Aug 2012, 10:53 PM Reply Like
  • holydawn
    , contributor
    Comments (139) | Send Message
    I believe they are referring to the necessary capital and distribution PFE provides to help launch the drug. It's so expensive to produce an FDA approved drug that few companies are able to to pull it off w/o help due to the high barriers set by the government to release drugs to market. If you don't have at least a billion dollars, it's like the government is saying don't even bother trying to develop a new drug, so that situation can't be helped. BTW, there is no guarantee ANY money is getting counted based solely on a successful trial. MANY drugs have done that and not seen the market for a variety of reasons.
    28 Aug 2012, 01:35 AM Reply Like
  • bernie 1
    , contributor
    Comments (569) | Send Message
    Just think of it this way taplinger, by the time MNKD & it's "blockbuster" has gotten this far,between 10 & 12 years have gone by. They have paid for Labs,scientists,even testing with both animal & human patients.
    A small company has great ideas & companies such as PFE has such deep pockets. They both can count that money,once the FDA is out of the way. Imagine what the sale-persons have to go to,the insurers, & I'm sure you realize what I'm saying.
    28 Aug 2012, 08:37 AM Reply Like
  • taplinger
    , contributor
    Comments (270) | Send Message
    Thank you holydawn and bernie1, I guess I had a vague memory of seeing stock exchange "greatest % increase today" and tiny drug firms rise 90% in a day on FDA approval.
    28 Aug 2012, 09:16 AM Reply Like
  • golfgod
    , contributor
    Comment (1) | Send Message
    Amen, to Bernie. After approval an intolerable amount of time can elapse before you can sell your drug. Then you must mass produce it and market it. Failing in either of these two areas can ruin you. Very small companies rarely even try it as they are very costly and must be accomplished perfectly. That is why partnering and cashing in on the
    licensing fees is the practical way to go. A company I am familiar with
    raised $10 million in a secondary offering just to try to accomplish production and marketing.
    28 Aug 2012, 03:52 PM Reply Like
  • taplinger
    , contributor
    Comments (270) | Send Message
    Funny how "big pharma" has become American's favorite industry to hate and how little people know about the expense of bringing a new drug to market - yet when people get sick they want a drug to make them better and they want it now! And even drug makers that are totally honest and ethical will get sued if years later there's an unforeseen side effect to one of their drugs.
    29 Aug 2012, 09:27 AM Reply Like
  • wecap
    , contributor
    Comments (44) | Send Message
    never buy a company on speculation of a takeover
    30 Aug 2012, 09:20 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs